DICE Therapeutics, Inc. (DICE) News
Filter DICE News Items
DICE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DICE News Highlights
- For DICE, its 30 day story count is now at 2.
- Over the past 25 days, the trend for DICE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- LLY are the most mentioned tickers in articles about DICE.
Latest DICE News From Around the Web
Below are the latest news stories about DICE THERAPEUTICS INC that investors may wish to consider to help them evaluate DICE as an investment opportunity.
Lilly Announces Extension of Tender Offer to Acquire DICEEli Lilly and Company (NYSE: LLY) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ("Shares") of common stock of DICE Therapeutics, Inc. (NASDAQ: DICE), for a purchase price of $48 per share in cash, without interest and less any applicable tax withholding. |
Cardlytics and Motorcar Parts of America Stock See Action From Activist InvestorsCAS Investment switched to an activist stance in digital-marketing company Cardlytics. Bison Capital increased its investment in retailer Motorcar Parts. |
Mergers Are Down, but These 2 Sectors Are BoomingTotal deal value worldwide is about $1.22 trillion year to date, according to data from London Stock Exchange Group. |
4 big deal reports: IBM to buy out Apptio for $5B, per media reportsHere is your Pro Recap of four head-turning deal dispatches you may have missed this week: IBM and Apptio merger rumors, Eli Lilly acquires Dice Therapeutics, Amazon's iRobot acquisition faces EU antitrust investigation, and Stratasys determines 3D Systems' offer not a 'Superior Proposal' to Desktop Metal agreement. InvestingPro subscribers got this news first. |
Why Dice Therapeutics Stock Bolted Higher This WeekThe big gain came after the company announced a $2.4 billion buyout agreement with industry heavyweight Eli Lilly (NYSE: LLY). Through this buyout, Lilly will add the experimental immunology medicines DC-806 and DC-853 to its pipeline. DC-806 is presently in midstage testing as a treatment for psoriasis. |
DICE Therapeutics (DICE) Up 37% on Buyout Offer from Eli LillyDICE Therapeutics (DICE) is set to be acquired by pharma-giant Eli Lilly (LLY) in an all-cash transaction for $2.4 billion. The transaction will likely close by third-quarter 2023. |
Is Eli Lilly's Dice Therapeutics Acquisition a Needle-Moving Event?The pharma giant's latest acquisition might be on the small side, but it could yield an important new growth driver in the years ahead. |
PLTR Stock Alert: Why Raymond James Just Downgraded PalantirPalantir (PLTR) stock is on the move Tuesday after Raymond James analysts downgraded the company's shares but increased its price target. |
RIVN Stock Alert: Rivian Jumps on the Tesla Bandwagon for EV ChargingRivian (RIVN) stock is in the news Tuesday as investors react to the electric vehicle (EV) company joining Tesla's (TSLA) charging standard. |
Why Is Dice Therapeutics (DICE) Stock Up 38% Today?Dice Therapeutics (DICE) stock is surging higher on Tuesday after Eli Lilly (LLY) announced plans to acquire the biopharmaceutical company. |